Penumbra, Inc.

NYSE:PEN

Medical - Devices

Healthcare
$320.60 -0.72%

-$2.30 today

Market cap
$12.64B
Beta
0.70
P/E (TTM)
72.6
EPS (TTM)
$4.36
52W Low $221.26High $362.41

Volume 0.21M

Average 0.50M

PEN Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Penumbra, Inc.NYSE: PEN

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue grows, but more slowly than its trailing trend

Q2 FY2026 revenue of $390.05M rose 14.9% year over year, behind the +17.6% change in trailing-twelve-month revenue. Sequentially, it rose 4.1% from the prior quarter. Over 3 fiscal years it compounded at +18.3% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 6 analysts of $1.6B (+14.0%) for the fiscal year ending Dec 2026, a slowdown from the +17.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$390.05M+4.1% QoQ
Last fiscal yearDec 2025
$1.4B+17.5% YoY
LTMJun 2026
$1.5B+17.6% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.9%+13.2%-1.7 pp
1 year+17.5%+14.0%-3.5 pp
3-year CAGR+18.3%+13.6%-4.7 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
1.4B USD
Year-over-year change
+17.5%
4-year CAGR
+17.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How PEN compares with its peers on the latest reported figures

  • PEN's LTM Jun 2026 revenue of $1.5B is the 7th highest of the 9 companies compared; the peer median is $9.05B.
  • Its year-over-year change of +17.6% is the 2nd highest of 9, against a peer median of +12.0%.
  • Over three fiscal years its annual growth of +18.3% compares with a peer median of +7.4%.
PEN Competitors Peer median
Revenue for PEN and competitors
Company Period LTM YoY 3-year CAGR
ABTAbbott LaboratoriesLTM Sep 2026$48.23B +10.0%+0.5%
MDTMedtronic plcLTM Jul 2026$37.54B +9.8%+5.2%
BSXBoston Scientific CorporationLTM Jun 2026$21B +13.5%+16.5%
ISRGIntuitive Surgical, Inc.LTM Sep 2026$11.58B +20.5%+17.4%
EWEdwards Lifesciences CorporationLTM Jun 2026$6.51B +14.6%+4.1%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$1.61B +9.2%+9.6%
PENPenumbra, Inc.LTM Jun 2026$1.5B +17.6%+18.3%
ANGOAngioDynamics, Inc.LTM Feb 2026$313.73M +10.7%-2.6%
LMATLeMaitre Vascular, Inc.LTM Mar 2026$256.28M +13.3%+15.6%
Peer median (excluding PEN) $9.05B+12.0%+7.4%

Competitors are the stored peer set for PEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue747.59M847.13M1.06B1.19B1.4B
Cost of Revenue272.21M311.93M375.88M439.62M461.23M
Gross Profit475.38M535.21M682.64M755M942.44M
Gross Margin63.6%63.2%64.5%63.2%67.1%
Research & Development104.55M79.41M84.42M94.78M89.77M
Selling, General & Admin378.33M449.72M506.45M573.99M663.42M
Operating Expenses482.88M529.13M609.09M668.77M753.19M
Depreciation & Amortization16.41M24.32M27.26M23.7M17.47M
EBITDA7.84M29.96M108.65M45.99M223.91M
EBITDA Margin1.0%3.5%10.3%3.8%16.0%
Operating Income(7.5M)6.08M73.55M86.22M189.25M
Operating Margin-1.0%0.7%6.9%7.2%13.5%
Interest Income2.87M1.89M6.83M13.69M16.29M
Interest Expense1.93M1.75M1.74M1.42M1.31M
Other Income / Expenses(3M)(2.19M)6.1M(65.36M)15.88M
Income Before Tax(10.5M)3.89M79.65M20.87M205.13M
Pre-Tax Margin-1.4%0.5%7.5%1.7%14.6%
Income Tax Expense(13.13M)5.89M(11.3M)6.86M27.44M
Net Income5.28M(2M)90.95M14.01M177.69M
Net Margin0.7%-0.2%8.6%1.2%12.7%
EPS (Basic)0.14(0.05)2.370.364.57
EPS (Diluted)0.14(0.05)2.320.364.52
Weighted Avg Shares36.76M37.84M38.4M38.63M38.92M
Weighted Avg Shares (Diluted)37.88M37.84M39.22M39.27M39.29M

Penumbra, Inc.

NYSE:PEN

Intrinsic Alpha fair value

Locked

Current Price

$320.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.